查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1999103

黄体素市场：按产品类型、适应症、给药途径和最终用户分類的全球市场预测 – 2026-2032 年

Progesterone Market by Product Type, Indication, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年孕酮市场价值 16.8 亿美元，预计到 2026 年将成长至 19.1 亿美元，复合年增长率为 14.58%，到 2032 年将达到 43.6 亿美元。

主要市场统计数据
基准年 2025 16.8亿美元
预计年份：2026年 19.1亿美元
预测年份 2032 43.6亿美元
复合年增长率 (%) 14.58%

全面概述孕酮的临床重要性、其製剂的演变、法规环境及其对治疗和商业策略的影响。

孕酮仍然是生殖健康和治疗管理中的关键激素，其临床应用范围广泛，包括避孕、不孕症治疗和荷尔蒙补充疗法。孕酮在调节月经週期、维持怀孕和调节子宫内膜反应方面的生化作用，使其在临床上持续受到关注，并推动了製剂科学和给药途径优化方面的研究。

不断发展的临床实践、监管重点、剂量创新和生产策略如何重新定义整个孕酮生态系统的价值创造。

黄体素市场的发展并非仅仅体现在产品分阶段的更新换代，而是反映了临床实践、生产製造以及整个商业模式的系统性变革。药物传递技术的进步推动了局部阴道给药疗法在子宫内膜保护和不孕症治疗中的广泛应用，同时注射剂和皮下製剂也在不断改进，以实现更可预测的药物动力学和更高的患者便利性。

积极主动管理关税变化对孕酮供应链和采购趋势的累积营运和合约影响的策略。

为应对计划于2025年实施的关税调整和贸易政策更新，製造商、经销商和医疗保健系统必须重新评估其与孕酮采购和製剂生产相关的供应链的韧性和成本结构。关税调整可能会影响活性成分、进口製剂成分和成品的采购，进而对筹资策略和合约谈判产生连锁反应。

详细的细分揭示了产品、适应症、给药途径和最终用户之间的差异，这些差异会影响临床区分、证据要求和商业性定位。

精细化的市场区隔观点能够清楚地揭示不同产品类型、适应症、给药途径和终端用户的需求驱动因素和创新机会。依产品类型划分，市场涵盖天然和合成孕激素，其中合成孕激素可细分为Medroxyprogesterone和炔诺酮。这种细分会影响製剂选择、专利格局和临床医生的偏好，因为天然和合成分子各自具有不同的药理特性和生产流程要求。依适应症划分，用途包括避孕、生育治疗和荷尔蒙补充疗法。避孕类别进一步细分为复方口服避孕药和黄体素单一疗法；生育类别分为辅助生殖技术和促排卵；荷尔蒙补充疗法分为子宫内膜保护和更年期管理。每种亚适应症都有其独特的临床终点、依从性挑战和支付方考量，这些都会影响产品定位和证据要求。

区域法规、基础设施和支付方趋势决定了全球市场的准入途径、分销复杂性和策略重点。

区域趋势对市场准入、监管合规和市场优先事项的影响至关重要，而这些因素对策略规划至关重要。在美洲，医疗保健系统的整合、支付方主导的处方药清单管理以及临床指南的广泛应用正在影响采购週期和对证据的期望。私人和公共支付者都会严格评估治疗价值，并且通常要求提供新型或改良型孕酮製剂的比较数据和成本效益证据。在欧洲、中东和非洲，法规结构和报销环境的多样性既带来了挑战，也带来了机会。一些司法管辖区的集中核准系统与各国特有的准入壁垒并存，这就需要根据当地情况定制申请文件和相关人员参与策略。同时，在非洲和中东部分地区，供应链的脆弱性和基础设施的限制凸显了建立稳健的经销伙伴关係和简化供应链的必要性。

企业策略、伙伴关係和製造敏捷性如何塑造孕酮产品系列中的竞争定位，并实现基于证据的差异化。

黄体素领域的企业策略日益呈现创新投资、伙伴关係和生产灵活性三者融合的趋势。原厂药企业不断研发新的製剂、给药系统和联合治疗，以满足未被满足的医疗需求，并在以患者为中心的疗效方面脱颖而出。同时，非专利生产商和合约研发生产机构（CDMO）也积极寻求监管途径，以优化生产效率、缩短产品上市时间并证明生物等效性。

高阶主管面临的实际策略挑战是如何将创新、监管应对力和供应链韧性与有针对性的商业化和伙伴关係模式结合。

产业领导者应采取综合策略，协调研发投入、监管策略和供应链韧性，以降低风险并抓住机会。首先，应优先考虑旨在带来临床意义显着获益的製剂创新，例如改善局部给药、减少全身副作用和提高遵守用药，并调整临床开发项目，以製定对支付方和医疗服务提供者至关重要的具体终点。其次，应加强监管和市场进入职能，并设计申请文件以支持在不同司法管辖区进行报销谈判，同时预见真实世界证据和上市后安全性监测要求的变化。

我们进行了一项混合方法调查，结合了相关人员访谈、监管和临床文献整合、专利检索和情境分析，以确保获得严谨而实用的见解。

本研究途径结合了第一手资料和第二手资料，以获得可靠且实用的见解。第一手资料包括对妇产科、生殖内分泌科和医院药房的临床医生进行访谈，以了解影响患者用药依从性的临床决策因素和考虑因素。此外，还与采购经理和监管事务专家进行了讨论，以深入了解准入障碍和申请要求。第二手资料则整合了同侪审查文献、监管指导文件、临床指南、专利和安全资料库，以全面检验临床疗效、安全性趋势和智慧财产权趋势。

临床意义、剂量创新、监管压力和营运准备的整合决定了整个孕酮价值链的竞争成功。

孕酮领域的不断演变为创新者、生产者和医疗保健提供者带来了机会和挑战。孕酮在避孕、生育治疗和更年期管理等方面的治疗重要性确保了其持续受到临床关注，而给药技术的进步和对循证医学日益增长的需求则为实现有意义的差异化提供了途径。同时，贸易政策的变化、围绕安全性和真实世界数据（REW）的监管力度加大以及不同地区获取途径的差异，都要求企业制定周密的战略规划。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：孕酮市场：依产品类型划分

  • 天然孕酮
  • 合成黄体素
    • Medroxyprogesterone
    • 去甲睾酮

第九章：孕酮市场：依适应症划分

  • 避孕药
    • 复方口服避孕药
    • 仅含黄体素的避孕药
  • 不孕症治疗
    • 辅助生殖技术
    • 诱导排卵
  • 荷尔蒙补充疗法
    • 子宫内膜保护
    • 更年期管理

第十章：孕酮市场：依给药途径划分

  • 注射药物
    • 肌肉内注射
    • 皮下注射
  • 口服
  • 经皮
  • 阴道使用
    • 阴道凝胶
    • 阴道栓剂
    • 阴道片

第十一章：孕酮市场：依最终用户划分

  • 诊所
  • 家庭医疗保健
  • 医院

第十二章：孕酮市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：孕酮市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 孕酮市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国黄体素市场

第十六章：中国黄体素市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Balchem Corporation
  • BASF SE
  • Bayer AG
  • Caldic BV
  • Ferring International Center SA
  • Gnosis SpA
  • Laboratoires Besins International
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Pharmascience Inc.
  • Strides Pharma Science Limited
  • Teva Pharmaceutical Industries Ltd
Product Code: MRR-E3708867712D

The Progesterone Market was valued at USD 1.68 billion in 2025 and is projected to grow to USD 1.91 billion in 2026, with a CAGR of 14.58%, reaching USD 4.36 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.68 billion
Estimated Year [2026] USD 1.91 billion
Forecast Year [2032] USD 4.36 billion
CAGR (%) 14.58%

Comprehensive orientation to progesterone's clinical importance, formulation evolution, regulatory environment, and implications for therapeutic and commercial strategy

Progesterone remains a cornerstone hormone in reproductive health and therapeutic management, with a breadth of clinical applications that span contraception, fertility support, and hormone replacement therapy. Its biochemical role in regulating menstrual cycles, supporting gestation, and modulating endometrial response underpins sustained clinical demand and continued scientific interest in formulation science and route-of-administration optimization.

Recent advances in synthetic analogues, delivery systems, and companion diagnostics have reshaped the way clinicians prescribe and patients adhere to progesterone-based regimens. Concurrently, evolving regulatory expectations and heightened scrutiny around pharmacovigilance have compelled manufacturers and clinical stakeholders to prioritize safety data, bioequivalence strategies, and post-market surveillance. Transitioning from traditional tablet regimens toward diversified formats such as transdermal systems and vaginal formulations reflects both patient preference trends and the push for targeted local effects with reduced systemic exposure.

Taken together, these dynamics underscore a complex landscape in which therapeutic rationale, formulation innovation, and health-system adoption converge. The introduction sets the stage for a detailed examination of transformative shifts, policy impacts, segmentation nuances, regional differentials, corporate strategies, and practical recommendations for industry leaders seeking to navigate this evolving environment.

How evolving clinical practice, regulatory emphasis, delivery innovations, and manufacturing strategies are redefining value creation across the progesterone ecosystem

The progesterone landscape is shifting in ways that extend beyond incremental product updates and instead reflect systemic transformation across clinical practice, manufacturing, and commercial models. Advances in drug delivery technology have enabled localized vaginal therapies to gain traction for endometrial protection and fertility support, while injectable and subcutaneous options are being refined for more predictable pharmacokinetics and improved patient convenience.

Regulatory shifts are also driving change. Agencies are increasingly focused on real-world safety data and comparative effectiveness, prompting companies to invest in robust post-market evidence generation and to design trials that capture quality-of-life outcomes alongside traditional endpoints. Precision medicine trends intersect with reproductive health as clinicians seek to tailor progesterone therapies according to patient phenotypes and treatment goals, which in turn influences formulary decisions and prescribing patterns.

On the commercial front, strategic partnerships between clinical service providers and manufacturers are becoming more common, enabling integrated care pathways that bundle diagnostics, therapy, and monitoring. Additionally, manufacturing strategies are evolving to prioritize flexible capacity and geographic diversification to mitigate supply disruption risks. Taken together, these transformative shifts are redefining how value is created and captured in the progesterone ecosystem and setting new expectations for agility, evidence generation, and patient-centric design.

Anticipatory strategies for managing the cumulative operational and contractual effects of tariff changes on progesterone supply chains and procurement dynamics

The prospect of tariff changes and trade policy updates in 2025 compels manufacturers, distributors, and health systems to reassess supply chain resilience and cost structures associated with progesterone sourcing and finished-dose production. Tariff adjustments can affect active pharmaceutical ingredient procurement, imported formulation components, and finished product shipments, creating cascading implications for sourcing strategies and contract negotiations.

In anticipation of trade shifts, stakeholders are evaluating alternative supply routes, nearshoring options, and strategic stockholding to maintain continuity of care. Procurement teams are negotiating longer-term supply agreements and exploring multi-sourcing arrangements for critical intermediates to reduce dependence on single-country suppliers. Meanwhile, quality assurance and regulatory compliance considerations remain paramount as firms alter sourcing strategies, since changes in supplier geography often necessitate additional audits and regulatory filings.

Moreover, payer and provider networks are factoring potential cost variability into formulary management and purchasing decisions. Clinics and hospitals are engaging with manufacturers to understand the implications of customs duties on pricing and reimbursement dynamics, while home healthcare providers are exploring operational levers to absorb or mitigate incremental costs. The cumulative effect of tariff-related policy shifts is therefore not limited to unit economics; it influences contractual terms, inventory management, and longer-term strategic planning across the progesterone value chain.

Detailed segmentation reveals product, indication, delivery, and end-user distinctions that drive clinical differentiation, evidence needs, and commercial positioning

A granular segmentation lens clarifies demand drivers and innovation opportunities across product types, indications, delivery pathways, and end users. Based on product type, the market encompasses both Natural Progesterone and Synthetic Progesterone, with Synthetic Progesterone further differentiated into Medroxyprogesterone Acetate and Norethisterone; this differentiation has implications for formulation choices, patent landscapes, and clinician preference, as natural and synthetic molecules present distinct pharmacology and manufacturing considerations. Based on indication, applications span Contraceptives, Fertility Treatments, and Hormone Replacement Therapy, where the Contraceptives category further subdivides into Combined Oral Contraceptive and Progestin-Only Pill, the Fertility Treatments segment differentiates into Assisted Reproductive Technology and Ovulation Induction, and Hormone Replacement Therapy is parsed into Endometrial Protection and Menopause Management; each sub-indication carries unique clinical endpoints, adherence challenges, and payer considerations that influence product positioning and evidence needs.

Based on route of administration, delivery formats include Injectable, Oral, Transdermal, and Vaginal, with the Injectable option further classified into Intramuscular Injection and Subcutaneous Injection and Vaginal delivery explored through Vaginal Gel, Vaginal Suppository, and Vaginal Tablet; route-specific preferences affect bioavailability profiles, manufacturing complexity, and patient adherence outcomes. Based on end user, the landscape comprises Clinics, Home Healthcare, and Hospitals, and each setting imposes different procurement processes, cold-chain or handling requirements, and interactions with prescribers and payers. Integrating these segmentation dimensions reveals areas of unmet need where formulation innovation, targeted clinical evidence, and tailored commercial strategies can unlock value and improve patient experience.

Region-specific regulatory, infrastructure, and payer dynamics that determine access pathways, distribution complexity, and strategic priorities across global markets

Regional dynamics shape access, regulatory navigation, and market priorities in ways that are essential for strategic planning. In the Americas, health-system consolidation, payer-driven formulary management, and a high degree of clinical guideline uptake influence procurement cycles and evidence expectations; private and public payers closely evaluate therapeutic value and often require comparative data or cost-effectiveness rationale for new or reformulated progesterone products. In Europe, Middle East & Africa, a heterogeneous mix of regulatory frameworks and reimbursement environments creates both challenges and opportunities: centralized approvals in some jurisdictions coexist with country-level access hurdles that require locally tailored dossiers and stakeholder engagement strategies. Meanwhile, in parts of Africa and the Middle East, supply chain fragility and infrastructure constraints underline the need for robust distribution partnerships and simplified delivery formats.

In the Asia-Pacific region, rapid growth in clinical services, expanding fertility-care infrastructure, and progressive regulatory reform in several markets are driving demand for diverse progesterone formulations. The region also exhibits strong manufacturing capabilities for active ingredients and generics, presenting opportunities for contract manufacturing and cost-competitive production. Across all regions, differences in cultural attitudes toward reproductive health, prescribing norms, and patient preferences necessitate nuanced market-entry plans and region-specific evidence generation, while cross-regional lessons on technology adoption and care models can inform scalable strategies.

How corporate strategies, partnerships, and manufacturing agility are shaping competitive positioning and enabling evidence-driven differentiation in progesterone portfolios

Corporate strategies in the progesterone sector are increasingly characterized by a blend of innovation investment, partnership formation, and manufacturing agility. Innovator companies continue to advance novel formulations, delivery systems, and combination therapies to address unmet clinical needs and differentiate on patient-centric outcomes. At the same time, generic manufacturers and contract development and manufacturing organizations are optimizing production efficiencies and pursuing regulatory pathways that demonstrate bioequivalence while minimizing time-to-market.

Strategic collaborations between pharmaceutical firms, specialty compounding providers, and clinical service networks are becoming more prevalent as stakeholders seek to deliver integrated care solutions that include diagnostics, therapeutics, and adherence support. Companies are also investing in real-world evidence capabilities and pharmacovigilance infrastructure to meet heightened regulatory expectations and to support payer negotiations. In parallel, some firms are focusing on geographic diversification of manufacturing and warehousing to reduce trade-related risk and to comply with localized regulatory requirements. Competitive differentiation increasingly depends on a company's ability to combine clinical credibility, supply reliability, and commercial agility, while aligning product portfolios with emerging treatment pathways and provider workflows.

Actionable strategic imperatives for executives to align innovation, regulatory readiness, and supply resilience with targeted commercialization and partnership models

Industry leaders should pursue integrated approaches that align research investment, regulatory strategy, and supply-chain resilience to capture opportunities while mitigating risk. First, prioritize formulation innovation targeted at clinically meaningful benefits such as improved local delivery, reduced systemic side effects, and enhanced adherence, and align clinical development programs to generate the specific endpoints payers and providers value. Second, strengthen regulatory and market-access functions to anticipate evolving requirements for real-world evidence and post-market safety monitoring, ensuring dossiers are designed to support reimbursement discussions across heterogeneous jurisdictions.

Third, invest in flexible manufacturing and diversified sourcing strategies to reduce exposure to trade disruptions and to shorten lead times for product introduction. Fourth, explore strategic partnerships with clinics, hospitals, and home-care providers to integrate therapy delivery with diagnostics and patient support services, thereby improving uptake and clinical outcomes. Fifth, develop targeted commercialization plans that reflect segmentation realities-product type, indication, route of administration, and end-user requirements-while applying regional insights to adapt messaging and evidence packages. By executing these coordinated actions, leaders can better navigate regulatory change, optimize value capture, and accelerate adoption across care settings.

Mixed-method research combining stakeholder interviews, regulatory and clinical literature synthesis, patent review, and scenario analysis to ensure rigorous and actionable insights

The research approach combined primary qualitative engagement with secondary synthesis to derive robust, practice-oriented findings. Primary research included interviews with clinicians across obstetrics, gynecology, reproductive endocrinology, and hospital pharmacy to capture clinical decision drivers and patient adherence considerations, supplemented by discussions with procurement leaders and regulatory affairs specialists to understand access barriers and submission requirements. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, clinical guideline statements, and patent and safety databases to triangulate clinical efficacy, safety trends, and intellectual property dynamics.

Analytical methods involved cross-validation of interview insights with document-based evidence, thematic coding to identify recurring commercial and clinical themes, and scenario analysis to explore supply-chain and policy contingencies. Quality control measures included source verification, expert peer review of interpretation, and adherence to transparent documentation practices to ensure reproducibility of findings. Wherever possible, regional granularity was derived by mapping regulatory frameworks and provider infrastructures against clinical practice patterns to produce actionable, jurisdiction-aware recommendations.

Synthesis of clinical relevance, delivery innovation, regulatory pressure, and operational readiness that determines competitive success across the progesterone value chain

The evolving progesterone landscape presents simultaneous opportunities and responsibilities for innovators, manufacturers, and care providers. Therapeutic relevance across contraception, fertility care, and menopause management ensures continued clinical focus, while advancements in delivery technology and evidence expectations create pathways for meaningful differentiation. At the same time, trade policy shifts, regulatory intensification around safety and real-world evidence, and regional heterogeneity in access mechanisms require deliberate strategic planning.

Synthesis of segmentation, regional, and corporate dynamics highlights that successful offerings will integrate clear clinical value, supply reliability, and adaptable commercialization strategies that reflect end-user realities. Companies that invest in targeted formulation work, evidence generation aligned to payer needs, and manufacturing flexibility will be positioned to respond to clinician preferences and patient expectations. Ultimately, the clinical utility of progesterone must be matched by commercial models and operational capabilities that deliver consistent access, transparent value propositions, and measurable outcomes in diverse care environments.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Progesterone Market, by Product Type

  • 8.1. Natural Progesterone
  • 8.2. Synthetic Progesterone
    • 8.2.1. Medroxyprogesterone Acetate
    • 8.2.2. Norethisterone

9. Progesterone Market, by Indication

  • 9.1. Contraceptives
    • 9.1.1. Combined Oral Contraceptive
    • 9.1.2. Progestin-Only Pill
  • 9.2. Fertility Treatments
    • 9.2.1. Assisted Reproductive Technology
    • 9.2.2. Ovulation Induction
  • 9.3. Hormone Replacement Therapy
    • 9.3.1. Endometrial Protection
    • 9.3.2. Menopause Management

10. Progesterone Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Intramuscular Injection
    • 10.1.2. Subcutaneous Injection
  • 10.2. Oral
  • 10.3. Transdermal
  • 10.4. Vaginal
    • 10.4.1. Vaginal Gel
    • 10.4.2. Vaginal Suppository
    • 10.4.3. Vaginal Tablet

11. Progesterone Market, by End User

  • 11.1. Clinics
  • 11.2. Home Healthcare
  • 11.3. Hospitals

12. Progesterone Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Progesterone Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Progesterone Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Progesterone Market

16. China Progesterone Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Balchem Corporation
  • 17.7. BASF SE
  • 17.8. Bayer AG
  • 17.9. Caldic B.V.
  • 17.10. Ferring International Center S.A.
  • 17.11. Gnosis S.p.A.
  • 17.12. Laboratoires Besins International
  • 17.13. Merck KGaA
  • 17.14. Novartis AG
  • 17.15. Pfizer Inc.
  • 17.16. Pharmascience Inc.
  • 17.17. Strides Pharma Science Limited
  • 17.18. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL PROGESTERONE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PROGESTERONE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PROGESTERONE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PROGESTERONE MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PROGESTERONE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PROGESTERONE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PROGESTERONE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PROGESTERONE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES PROGESTERONE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA PROGESTERONE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PROGESTERONE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PROGESTERONE MARKET SIZE, BY NATURAL PROGESTERONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PROGESTERONE MARKET SIZE, BY NATURAL PROGESTERONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PROGESTERONE MARKET SIZE, BY NATURAL PROGESTERONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PROGESTERONE MARKET SIZE, BY MEDROXYPROGESTERONE ACETATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROGESTERONE MARKET SIZE, BY MEDROXYPROGESTERONE ACETATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PROGESTERONE MARKET SIZE, BY MEDROXYPROGESTERONE ACETATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROGESTERONE MARKET SIZE, BY NORETHISTERONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PROGESTERONE MARKET SIZE, BY NORETHISTERONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROGESTERONE MARKET SIZE, BY NORETHISTERONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROGESTERONE MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PROGESTERONE MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROGESTERONE MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PROGESTERONE MARKET SIZE, BY PROGESTIN-ONLY PILL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PROGESTERONE MARKET SIZE, BY PROGESTIN-ONLY PILL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PROGESTERONE MARKET SIZE, BY PROGESTIN-ONLY PILL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROGESTERONE MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PROGESTERONE MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROGESTERONE MARKET SIZE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PROGESTERONE MARKET SIZE, BY OVULATION INDUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROGESTERONE MARKET SIZE, BY OVULATION INDUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PROGESTERONE MARKET SIZE, BY OVULATION INDUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROGESTERONE MARKET SIZE, BY ENDOMETRIAL PROTECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PROGESTERONE MARKET SIZE, BY ENDOMETRIAL PROTECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PROGESTERONE MARKET SIZE, BY ENDOMETRIAL PROTECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PROGESTERONE MARKET SIZE, BY MENOPAUSE MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PROGESTERONE MARKET SIZE, BY MENOPAUSE MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PROGESTERONE MARKET SIZE, BY MENOPAUSE MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PROGESTERONE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PROGESTERONE MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PROGESTERONE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PROGESTERONE MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROGESTERONE MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PROGESTERONE MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROGESTERONE MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PROGESTERONE MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PROGESTERONE MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PROGESTERONE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PROGESTERONE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PROGESTERONE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROGESTERONE MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PROGESTERONE MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PROGESTERONE MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL SUPPOSITORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL SUPPOSITORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL SUPPOSITORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PROGESTERONE MARKET SIZE, BY VAGINAL TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PROGESTERONE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PROGESTERONE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PROGESTERONE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PROGESTERONE MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PROGESTERONE MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PROGESTERONE MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PROGESTERONE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PROGESTERONE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PROGESTERONE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PROGESTERONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS PROGESTERONE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL PROGESTERONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GCC PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GCC PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. GCC PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 191. GCC PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 192. GCC PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 193. GCC PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 194. GCC PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. GCC PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 197. GCC PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 198. GCC PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. G7 PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. G7 PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. G7 PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 224. G7 PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 225. G7 PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 226. G7 PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 227. G7 PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. G7 PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 230. G7 PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 231. G7 PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. NATO PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. NATO PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. NATO PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 236. NATO PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 237. NATO PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 238. NATO PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. NATO PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 241. NATO PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 242. NATO PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL PROGESTERONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES PROGESTERONE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA PROGESTERONE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA PROGESTERONE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA PROGESTERONE MARKET SIZE, BY SYNTHETIC PROGESTERONE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA PROGESTERONE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA PROGESTERONE MARKET SIZE, BY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA PROGESTERONE MARKET SIZE, BY FERTILITY TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA PROGESTERONE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA PROGESTERONE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA PROGESTERONE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA PROGESTERONE MARKET SIZE, BY VAGINAL, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA PROGESTERONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)